Skip to main content

Videos

Samuel Kareff, MD, MPH: Good afternoon, everyone. Welcome to the Oncology Data Advisor Fellows Forum. We have a very special edition this week for National Cancer Prevention Month. Ironically, we're filming this on Mardi Gras, a day on which some folks may or may not participate in activities that are conducive to cancer development. At any rate, we're going to go ahead and launch right into the special edition today. On a more serious note, what we want to start off discussing here are some of ...
Jason Mouabbi, MD: Hello, everyone. I'm Jason Mouabbi. I'm a Breast Medical Oncologist at MD Anderson Cancer Center, and I'm a member of the Editorial Board at Oncology Data Advisor. Today, I have the pleasure to be joined by two guests—Ross Maclean, Executive Vice President of Precision Health Economics & Outcomes Research and the Head of Medical Affairs for Precision Value & Health, and Michael Glover, Partner at Qinexa Consultancy, LLC. Today, our topic is very, very interesting. It's...
In honor of Gallbladder and Bile Duct Cancer Awareness Month this February, Fellows Forum members Dr. Waqas Haque and Dr. Matthew Hadfield sat down for a discussion on the challenges in diagnosis of gallbladder and bile duct cancers and the importance of genetic sequencing for making targeted treatments available for patients.   Waqas Haque, MD, MPH: Hi everybody, thanks for joining our Oncology Data Advisor podcast today. My name is Waqas Haque. I'm a third-year Internal Medicine Resident ...
Richa Thakur, MD: Hi, I'm Richa Thakur. I'm one of the second-year Hematology/Oncology Fellows at Northwell Health, and I'm also one of the members of the Fellows Forum. Today, we have a really exciting episode for you because February 14th is National Donor Day. Since we're a medical oncology podcast, the type of tissue donor we're going to focus on is bone marrow. To everyone who has been a living donor or a deceased donor, thank you so much for your contributions. You have no idea what this g...
Oncology Data Advisor: All right, everyone, thank you so much for tuning into today's World Cancer Day panel featuring our Fellows Forum and Editorial Board members. We have a really thoughtful discussion planned for today on ways to improve cancer care on a global scale, including access to treatments in low-and-middle–income countries and barriers to molecular testing. Without further ado, I will turn it over to our panelists to introduce themselves and then dive into the conversation, so Dr. ...
Stephen Freedland, MD: Hello, I'm Steve Freedland, a Urologist at Cedars-Sinai Medical Center as well as the Durham Veterans Affairs (VA) Hospital in Durham, North Carolina. It's my great privilege and honor to be here today with my good friend and close colleague, Dr. William Aronson, Professor of Urology at UCLA and Chief of Urologic Oncology at the Greater Los Angeles VA Health System. Bill, it's great to have you here. We're talking prostate cancer prevention in light of National Cancer Prev...
Samuel Kareff, MD, MPH: Welcome, everyone, to another edition of the Fellows Forum. Today, I'm joined by Dr. Aman Chauhan, who is an Associate Professor of Medical Oncology at the University of Miami, Sylvester Comprehensive Cancer Center. He's the leader of our Neuroendocrine Tumor Program, as well as the Co-Director of our Theranostics Program. Dr. Chauhan, welcome. Aman Chauhan, MD: Thank you so much, Sam. How are you doing? Dr. Kareff: Doing well, thank you very much. I appreciate your time ...
Waqas Haque, MD, MPH: Hi, welcome everybody. I'm Waqas. I'm a third-year Internal Medicine Resident at New York University (NYU) on a Clinical Investigator Track, and I'm starting Oncology Fellowship at the University of Chicago this upcoming summer. I'm excited to bring you the next episode of the Oncology Data Advisor podcast. This week, we'll be having a feature from Leif Honda, who's the Chief Innovation Officer at TriMetis, a company dedicated to automating the workflow process through AI f...
Jason Mouabbi, MD: Good afternoon, everyone. I'm Dr. Jason Mouabbi. I'm a Breast Medical Oncologist in the Department of Breast Medical Oncology at MD Anderson Cancer Center, and I'm also one of the Editors of Oncology Data Advisor. I have the pleasure today to interview Dr. Carlos Doti, Head of Medical Affairs in the US at AstraZeneca. Welcome, Dr. Doti. Carlos Doti, MD: Thank you very much for having me. Dr. Mouabbi: This is very exciting. We heard recently about the FDA approval of capivasert...
Keira Smith: Thank you, everyone, for tuning in to the show today. We're so excited to be hosting this first episode of Oncology Data Advisor's new podcast series focused on artificial intelligence (AI) in cancer care. I'm joined today by our two co-hosts from the Oncology Data Advisor Fellows Forum, Dr. Waqas Haque and Dr. Matthew Hadfield. We have the honor of being joined today by Dr. Ofer Sharon, who is the CEO of OncoHost. We're really looking forward to hearing more about OncoHost and your...
Matthew Hadfield, DO: Good morning, everybody. I'm Matt Hatfield. I'm a current third-year Medical Oncology Fellow at Brown University in Providence, Rhode Island, and soon to be an attending, focusing on phase 1 early drug development. I'm super excited to have this conversation today with Dr. Ahmadi and Dr. Nielsen of Genmab and AbbVie, as well as my colleague, Dr. Taneja. Just to get us started, maybe we can start with some introductions. Jacqueline Nielsen, PhD: I'm Jackie Nielsen. I'm the T...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, I am joined by Dr. Jason Mouabbi, who is one of our Editorial Board members. Dr. Mouabbi recently returned from the 2023 San Antonio Breast Cancer Symposium, and today, he's here to talk about some of the highlights from the conference. Thank you so much for coming on the show today. Jason Mouabbi: Thank you for having me. It's always a pleasure to be here. We just came from a very interesting San Antonio Breast Cancer Symposium. A ...
Recently, the American Cancer Society recommended new lung cancer screening guidelines to shift the focus from quitting smoking, to helping all individuals who have smoked despite quitting 20 to 30 years prior. In this interview, Dr. Brian Whang, Medical Director of Lung Cancer Screening for Hartford Healthcare, discusses these new guidelines, what they mean, and why we should continue advocating for better lung cancer screening guidelines and awareness of this issue.   Oncology Data Adviso...
Stephen Freedland, MD: Hi, I'm Steve Freedland, Professor of Urology at Cedars-Sinai Medical Center in Los Angeles, as well as at the Durham Veterans Affairs (VA) Hospital in Durham, North Carolina. It's my great privilege and honor here today to be with a dear friend, a phenomenal investigator, Professor Neeraj Agrawal, who is a Professor of Medicine and the Director of the GU Medical Oncology Group at Huntsman Cancer Institute of the University of Utah. Welcome to the program, Neeraj. Neeraj A...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're excited to be discussing this week's expanded FDA approval of enzalutamide for nonmetastatic castration-sensitive prostate cancer with biochemical recurrence. I'm joined by Dr. Stephen Freedland, who co-led the study which led to the approval. Dr. Freedland, thanks so much for coming on today. Stephen Freedland, MD: Thanks for having me. It's certainly an exciting time to be here. Oncology Data Advisor: For a little bit of bac...
Oncology Data Advisor: Hi everyone, and welcome to this latest podcast collaboration between Oncology Data Advisor and MedNews Week. I'm Keira Smith, I'm the Senior Editor at Oncology Data Advisor. We have a pretty exciting episode today planned in honor of Lung Cancer Awareness Month. We'll be discussing some of the global perspectives in lung cancer that everybody brings to the table here. To start off, we'll go around and have everyone introduce themselves. Starting with the OncData side, Dr....
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're having this interview in honor of the Great American Smokeout®, which is a day for raising awareness around smoking and sharing resources for people who are trying to take the first step towards quitting. The aspect of this that we're focusing on today is the link between prostate cancer and smoking, and here today to talk about this is one of our Editorial Board members, Dr. Stephen Freedland. Thanks so much for coming on tod...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're having this interview in honor of Pancreatic Cancer Awareness Month. I'm joined by one of our Editorial Board members, Dr. Joe Kalis, who is an Ambulatory Oncology Clinical Pharmacy Specialist at the University of Colorado Health. He's here to discuss some of the challenges related to diagnosis and screening of pancreatic cancer, as well as the ongoing research in these areas. Dr. Kalis, thanks so much for coming on the show t...
Recently, Tanya Dorff, MD, Division Chief of the Genitourinary Disease Program at City of Hope, served as faculty for i3 Health's CME/NCPD-approved activity, Evolving Treatment Concepts and New Data in Advanced Prostate Cancer. Since recording, a plethora of new data and treatment options have been made available for prostate cancer, as well as additional ongoing and future clinical trials to look forward to. In this interview, Dr. Dorff catches us up to speed on these new advancements and share...
With the complex and rapidly evolving treatment landscape of multiple myeloma, it is vital that clinicians not only understand factors for informing selection of current and emerging combination and sequential therapeutic strategies, but also employ interdisciplinary strategies for reducing disparities in relapsed/refractory multiple myeloma care. The development of novel therapeutic options has significantly improved treatment outcomes for patients with relapsed/refractory multiple myeloma; how...
Rahul Banerjee, MD, FACP: Welcome back to Oncology Data Advisor. My name is Rahul Banerjee, and I'm one of the Board Members of Oncology Data Advisor. I'm also an Assistant Professor of Medicine at the Fred Hutchinson Cancer Center in Seattle. Today, it's my pleasure to be joined by Dr. Andrew Yee. Dr. Yee is a Clinical Director for Multiple Myeloma at Massachusetts General Hospital in Boston. He's also an Assistant Professor of Medicine at Harvard Medical School. He specializes in multiple myel...
Oncology Data Advisor: Hi, everyone. Thanks so much for tuning in tonight for this Lung Cancer Awareness Month panel discussion. I'm joined by a few members of our Fellows Forum. We have Dr. Sam Kareff, who is a Hematology/Oncology Fellow at the University of Miami; we have Dr. Waqas Haque, who is a third-year Internal Medicine Resident at New York University; and we have Dr. Matt Hadfield, who is a Hematology/Oncology Fellow at Brown University. We'll be talking today about some recent research...
This Fellows Forum episode features Dr. Samuel Kareff and Dr. Matthew Hadfield in a discussion about unique ways to create educational opportunities during Hematology/Oncology Fellowship, including board exam preparation, methods for teaching residents and other fellows, and the value of live and virtual onsite continuing medical education (CME) meetings.   Samuel Kareff, MD, MPH: Hi, everyone. Welcome to the next episode of the Oncology Data Advisor Fellows Forum. Today, I'm joined by Dr. ...
Rahul Banerjee, MD, FACP: Hi, everyone. Welcome back to Oncology Data Advisor. My name is Rahul Banerjee. I'm an Assistant Professor of Medicine at the Fred Hutchinson Cancer Center in Seattle, Washington. Today, it's my pleasure to speak with Dr. Shonali Midha to get some updates from the 2023 International Myeloma Society Meeting that took place at the end of September in Athens, Greece. Dr. Midha is a myeloma expert at the Dana-Farber Cancer Institute in Boston, Massachusetts, and an Instruct...
Oncology Data Advisor: Welcome to Oncology Data Advisor. On today's episode for Breast Cancer Awareness Month, we're focusing on misperceptions surrounding metastatic breast cancer. I'm joined by Janie Metsker, who is the Clinical Coordinator and Nurse Navigator at St. Luke's Koontz Center for Advanced Breast Cancer. Janie, thanks so much for coming on the show today. Janie Metsker, RN, BSN, CN-BN: Thank you for having me today. I'm really excited to share this topic with you. I am the Clinical ...
At this year's European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, Dr. Kevin Kalinsky, Director of the Glenn Family Breast Center at Winship Cancer Institute of Emory University, presented the results of real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line or later treatment of metastatic triple-negative breast cancer (TNBC). In this interview, he gives us further insight to the results he shared and what these results could mean f...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, I'm joined by Dr. Henry Park, who is the Chief of Thoracic Radiotherapy at Yale School of Medicine, Smilow Cancer Network. Last year, Dr. Park served as faculty for i3 Health's CME/NCPD/CPE–approved activity on Optimizing Treatment Selection, Sequencing, and Tolerability in Small Cell Lung Cancer (SCLC). Today, he's here to share some updates that have occurred in the field since then, including data presented just this month at the...
Oncology Data Advisor: Hi, and welcome to Oncology Data Advisor. Today, in honor of Breast Cancer Awareness Month, we're having this interview with Dr. Connie Visovsky. Thanks so much for coming on today. Connie Visovsky, PhD, RN, ACNP, FAAN: Thank you for inviting me. I'm very excited to be here with you today. As you said, Keira, I'm Connie Visovsky. I am a Professor and the Hughes Endowed Chair in Nursing Science at the University of South Florida in Tampa. I've been studying peripheral neuro...
Do you have questions about the diagnosis, treatment, or management of breast cancer? Download the Triple-Negative Breast Cancer (TNBC) Pocket Guide App to ask your questions and receive an answer from breast oncology and pathology experts!   Oncology Data Advisor: Welcome to Oncology Data Advisor. Today we have an interview for Breast Cancer Awareness Month, and I'm joined by Dr. Jason Mouabbi. Dr. Mouabbi, thanks so much for coming on the show today. Jason Mouabbi, MD: Thank you for havin...
Oncology Data Advisor: Welcome to Oncology Data Advisor. I'm Keira Smith, and today I have the pleasure of being joined by Marcus Engel, who is a renowned health care speaker, author, and compassion consultant. Marcus has written four books and hosts the Compassion & Courage: Conversations in Healthcare podcast. Marcus, it's such an honor to have you on the show today. Marcus Engel, MS, CXCP, CPS: Thank you. Likewise, it's good to be with you. Oncology Data Advisor: To start off, I'd love to...
Oncology Data Advisor: Welcome to Oncology Data Advisor. I'm Keira Smith, and today I have the pleasure of being joined by Molly MacDonald, who is the Founder of Pink Fund. Molly, thank you so much for coming on the show today. Molly MacDonald: Thank you for having me. Oncology Data Advisor: Would you like to start off giving a brief intro about yourself? Ms. MacDonald: Certainly. With respect to the work that I have the privilege to do now, which is mission-based, I was diagnosed at a time of j...
In this interview, Dr. Nagashree Seetharamu, MD, MBBS, a Professor in the Division of Hematology and Medical Oncology in the Department of Medicine at Hofstra Northwell Health, sat down to discuss the vital role that exercise takes in the cancer treatment and recovery process. As well, she shares advice on why an individualized approach to a patient's exercise routine and care is crucial to their survivorship.   Oncology Data Advisor: Thank you, Dr. Seetharamu, for meeting with me today to ...
In this Oncology Data Advisor Fellows Forum interview, Dr. Matthew Hadfield, Medical Oncology Fellow at Brown University, and Dr. Richa Thakur, Hematology/Oncology Fellow at Northwell Health, explore the different types of educational opportunities available during fellowship, including podcasts and in-person meetings, and strategies for finding the most up-to-date education. Visit i3Health.com to explore the FREE live hematology/oncology meeting series offered by i3 Health, and book one fo...
In this interview, Thomas Powles, MD, MBBS, MRCP, Director of the Barts Cancer Center in London, sat down with Oncology Data Advisor to discuss the results of the EV-302 trial, a phase 3, open-label investigation of enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial cancer.   Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, I have the honor of being joined by Dr. Thomas Powles to discuss the results of the EV-302 trial. Dr...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, I have the honor of being joined by Dr. Dhodapkar, who is here to discuss the results of a trial presented at the IMS Meeting. Dr. Dhodapkar, thank you so much for coming on today. Madhav Dhodapkar, MD: It's really a pleasure. Again, my name is Madhav Dhodapkar. I'm a Professor of Hematology and Medical Oncology at Emory University. I'm here at the International Myeloma Society meeting in Greece to discuss the results of a clinical ...
Oncology Data Advisor: Hi everybody, welcome to Oncology Data Advisor. I'm Keira Smith. I'm the Senior Editor at OncData, and today, we're really excited to be hosting this panel discussion in honor of World Cancer Research Day. I have the pleasure of being joined by a few members of our Fellows Forum and Editorial Board. We have Dr. Samuel Kareff, who is the Chief Hematology/Oncology Fellow at the University of Miami Sylvester Cancer Center. We have Maria Badillo, who is the Research Nurse Mana...
Rahul Banerjee, MD, FACP: Welcome to Oncology Data Advisor. My name is Rahul Banerjee. I'm Assistant Professor of Medicine at the Fred Hutchinson Cancer Center in Seattle. September is Blood Cancer Awareness Month and as a result, we're doing several episodes this month around multiple myeloma. Today, it is my honor to speak with Dr. Gurbakhash Kaur about dosing of medications in myeloma—twice-weekly, biweekly, or somewhere in between. Dr. Kaur is an Assistant Professor of Medicine at the Univer...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're having a Fellows Forum interview, and I'm joined by Dr. Matt Hadfield. Thanks so much for coming on today. Matthew Hadfield, DO: Thank you so much for having me. Oncology Data Advisor: To start off, would you like to share a little bit about yourself and what you do and your work? Dr. Hadfield: Yes, I am a third-year Hematology/Oncology Fellow at Brown University in the Legoretta Cancer Center in Providence, Rhode Island. I pr...
Oncology Data Advisor: Would you like to tell us about yourself and your career in research? Waqas Haque, MD: Hey everybody, I'm Waqas. I'm a third-year Internal Medicine Resident at NYU in the Clinical Investigator Track. For medical school, I went to the University of Texas (UT) Southwestern in Dallas, Texas, which is where I grew up. There, I was involved in a project for my dissertation on the financial and clinical utility of Foundation Medicine testing at our institution's cancer center. I...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, I have the pleasure of being joined by one of our Editorial Board members, Dr. Lauren Ghazal. Thanks so much for coming on today. Lauren Ghazal, PhD, FNP-BC: Thanks for having me. Oncology Data Advisor: To start off, would you like to share a little bit of an intro about yourself? Dr. Ghazal: Oh, yes. Hello everyone, my name is Lauren Ghazal. I am currently an Assistant Professor at the University of Rochester and a Family Nurse Pra...
Recently, the FDA approved melphalan for liver-directed treatment of uveal melanoma. In this interview, Oncology Data Advisor Editorial Board member Dr. Richard Carvajal, Deputy Physician-in-Chief and Director of Medical Oncology at Northwell Health Cancer Institute in New York, discusses the approval and the trial that led to it, as well as share exciting insights on the potential future landscape of this rare disease.   Oncology Data Advisor: Welcome to Oncology Data Advisor, a digital re...
Keira Smith: Good morning, everyone. Welcome to this podcast, which is a collaboration between Oncology Data Advisor and MedNews Week. We're really excited today to have this podcast and to join forces and discuss some of the topics in oncology that we're all passionate about. We'll go around and introduce everybody. To start off, I'm Keira Smith. I'm the Senior Editor at Oncology Data Advisor. I plan and manage the content that OncData puts out, and I also liaison with our Editorial Board and o...
Oncology Data Advisor: Welcome to Oncology Data Advisor. I'm Keira Smith. Today, we're having this interview in honor of Pain Awareness Month, and I'm joined by Dr. Nida Khan, who is one of our Fellows Forum members, and Dr. Joseph Kalis, who is one of our Editorial Board members. Thank you both so much for coming on the show today. Nida Khan, MD: Thank you, thanks for having us. Joseph Kalis, PharmD, BCOP: Yes, you're very welcome. I'm excited to be here. Oncology Data Advisor: Would you both l...
Oncology Data Advisor: Welcome to Oncology Data Advisor. I'm Keira Smith, and today I am joined by one of our Editorial Board Members, Dr. Ulka Vaishampayan. Thank you so much for coming on today. Ulka Vaishampayan, MD: Thank you. Oncology Data Advisor: We're having this interview today in honor of September being Prostate Cancer Awareness Month. In your opinion, why is it so important to raise awareness for prostate cancer? Dr. Vaishampayan: Prostate cancer is very common. About one in four men...
Stephen Freedland, MD: Thank you so much for joining us, everyone. I'm Steve Freedland. I'm a Urologist at Cedars-Sinai Medical Center in Los Angeles, as well as at the Durham VA Hospital in Durham, North Carolina. Thank you for joining us on Oncology Data Advisor for Prostate Cancer Awareness Month. I'm super excited that we have a great special guest here, Dr. Farnoosh Nik-Ahd. Dr. Farnoosh Nik-Ahd is a Resident in Urology at UCSF. She went to medical school at the University of California, Lo...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, I have the pleasure of being joined by Dr. Jesus Garcia. Thanks so much for coming on today. Jesus Garcia, PhD: Thank you. Oncology Data Advisor: Would you like to introduce yourself and share a little bit about what your work and your research focus on? Dr. Garcia: Sure. So, I'm originally from Mexico. That's where I went to college. I originally came to the United States for grad school. I did all my research in collaboration with...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're having this interview in honor of Appendix Cancer Awareness Month, and I'm joined by our Editor-in-Chief, Dr. Thomas Abrams. Thomas Abrams, MD: Thank you so much for having me, Keira. It's always a pleasure to give a little bit of an overview of a disease I treat and that I see a lot of patients with. Appendiceal cancers are a rare group of malignancies, and we just don't see enough of these patients to build up enough of a cl...
Oncology Data Advisor holds the utmost value for patient advocates and advocacy groups as they strive to prioritize patient-centered care and shared decision making throughout the cancer journey. At this year's American Society of Clinical Oncology (ASCO) Annual Meeting, Oncology Data Advisor spoke with numerous individuals representing diverse aspects of oncology and asked them how they strive to partner with patients in their practice, research, and advocacy work.   Allison Rosen, Patient...
This Oncology Data Advisor Fellows Forum interview celebrates National Immunization Awareness Month, featuring Richa Thakur, MD, Hematology/Oncology (Heme/Onc) Fellow at Northwell Health, and Waqas Haque, MD, Internal Medicine Resident at New York University, in a discussion about the importance of immunizations for cancer patients, their friends and family, and in general, as well as advice for clinicians on approaching the topic of immunizations with their patients.   Richa Thakur, MD: Hi...
Oncology Data Advisor: Welcome to Oncology Data Advisor. I'm Kera Smith, and today I'm joined by Dr. Reid Merryman. Dr. Merryman, it's nice to talk to you again. Reid Merryman, MD: Great to be here. Oncology Data Advisor: So, last month, we talked about the recent approval of epcoritamab for diffuse large B-cell lymphoma (DLBCL). Recently, results were also presented for epcoritamab for follicular lymphoma. What is this trial investigating in comparison to the trial that the approval was based o...
Oncology Data Advisor: Welcome to Oncology Data Advisor. I'm Keira Smith, and today I'm joined by Dr. Ofer Sharon. Thanks so much for coming on today. Ofer Sharon, MD: Thanks for having me. It's a pleasure to be here. Oncology Data Advisor: To start off, would you like to introduce yourself and then share a little bit about OncoHost as well? Dr. Sharon: Of course, I'd be happy to. I'm Ofer, and I'm the CEO of OncoHost. I am a Physician by training. I'm an Internist, but I've spent most of my car...
Oncology Data Advisor: Welcome to Oncology Data Advisor. I'm Keira Smith, and today I have the pleasure of being joined by Megan-Claire Chase. Thanks so much for coming on today. Megan-Claire Chase: Thanks so much for having me. Oncology Data Advisor: Would you like to introduce yourself and share a short overview of what you do in your work for cancer awareness? Ms. Chase: Yes, I'm known in the cancer space as "Warrior Megsie." I am a soon-to-be seven-year, come October, invasive lobular breast...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're here at the ASCO Annual Meeting, and I'm joined by Dr. Stephen Freedland. Thanks for coming on today. Stephen Freedland, MD: Hello, absolutely. Thanks for having me. Oncology Data Advisor: Would you like to introduce yourself and share what your work and your research focus on? Dr. Freedland: Yes, I'm Steve Freedland. I'm a urologist—a little bit of out of place here at ASCO, but it's fun to be here. I'm at Cedars-Sinai Medica...
Oncology Data Advisor: Today, we're at the ASCO Annual Meeting, and I'm joined by Robin Lally and Marilyn Hammer. Thank you both so much for coming on today. Robin Lally, PhD: Thank you, it's very nice to be here. Oncology Data Advisor: Would you like to introduce yourselves and share what your work and your research focus on? Dr. Lally: Sure, I'm Dr. Robin Lally. I'm a Professor in the College of Nursing at the University of Nebraska Medical Center's Fred & Pamela Buffett Cancer Center. My ...
i3 Health recently hosted Pathology and Oncology Expert Perspectives in the Management of Triple-Negative Breast Cancer (TNBC): Case Explorations and Answers to FAQs, an accredited CME/NCPD webinar now available on the i3 Health website. In this video interview, Dr. Tolaney shares a preview of the important topics discussed in the activity, including approaches to treatment selection, the emerging role of novel therapies, timely management of adverse events, and much more. Oncology Data Advisor:...
Oncology Data Advisor: Thanks so much for coming on today. Allison Rosen, MS: Of course. Happy to be here. Oncology Data Advisor: Would you like to introduce yourself and share a little bit about your story and how you became involved in patient advocacy? Oncology Data Advisor: Sure. I'm a 10-year colorectal cancer survivor. Ten years ago, I was working in cancer research and living life to the fullest—working out, going out, having a great time. I started having interesting symptoms that I had ...
Samuel Kareff, MD, MPH: Hello, and welcome to this episode of Oncology Data Advisor's Fellows Forum. This is a new resource featuring expert perspectives geared towards Hematology and Medical Oncology Fellows. Today, I'm humbled to be joined by Dr. Ana Velazquez Mañana. She carries several titles, a few of which I'll mention here. She's an Assistant Professor of Medicine in the UCSF Division of Hematology-Oncology at Zuckerberg San Francisco General. She's a Thoracic Oncologist at the UCSF Helen...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're here at the ASCO Annual Meeting in Chicago, and I'm joined by Dr. Tom Abrams, who is our Editor in Chief. Thomas Abrams, MD: I'm so happy to be here. It's been a great meeting, and I'm just happy to get in front of the camera here and do a podcast. Oncology Data Advisor: Yes, definitely. How are you enjoying your time at ASCO so far? Dr. Abrams: It's been great. It's a whirlwind of a meeting, but you get to reconnect with a lo...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're here at the ASCO Annual Meeting, and I'm joined by Dr. Yan Leyfman. Thanks so much for coming on today. Yan Leyfman, MD: Thank you so much for having me. It's truly a pleasure to be here. Oncology Data Advisor: Would you like to introduce yourself and your platform, MedNews Week? Dr. Leyfman: Sure, thank you so much for the opportunity. I am a physician and a researcher from Mount Sinai, New York. During the height of the COVI...
In this Oncology Data Advisor® Fellows Forum interview, member Waqas Haque, MD, an Internal Medicine Resident at New York University, shares his medical training journey, the research he has conducted as Clinical Investigator Track Resident, his plans for applying to an oncology fellowship, advice for navigating the experience, tips for acquiring oncology exposure during residency, and much more!   Oncology Data Advisor: Welcome to the Oncology Data Advisor Fellows Forum. Today, I'm joined ...
Richa Thakur, MD: Hi, I'm Richa Thakur. I'm a first-year Hematology/Oncology (Heme/Onc) Fellow at Northwell, and I'm one of the members of the Fellows Forum. Today, I'm really excited to introduce you to Dr. Nida Khan. She's a third-year Medicine Resident at Northwell as well, and in July, she's going to be starting her first year of a joint Medical Oncology and Palliative Care Fellowship in Ohio. I'm really excited to bring her, because these programs are so new, and I really can't wait for you...
Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today, I'm joined by Dr. Reid Merryman from Dana-Farber Cancer Institute, who is a primary investigator of the EPCORE NHL-1 trial that recently led to the approval of epcoritamab for diffuse large B-cell lymphoma. Dr. Merryman, thank you so much for joining today. To start off, would you like to introduce yourself and share what your work focuses on? Reid Merryman, MD: My name's Reid Merryman. I'm one of the lymphoma docto...

Oncology Data Advisor® · Live Podcasts From the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we are here at ONS Congress, and I'm joined by Janie Metsker. Thank you so much for coming on today. Janie Metsker, RN, BSN, CN-BN: Thank you for having me. Oncology Data Advisor: It's nice to finally meet you in person. I know we've done a couple of virtual interviews before, so this is great. Ms. Metsker: Yes, it's nice to meet you as well, and your team. Oncology Data Advisor: Would you like to start off by introducing yourself a...
This year's Oncology Nursing Society (ONS) Congress featured numerous thought-provoking and motivating presentations from experts in the field of oncology nursing. Maria Badillo, Research Nurse Manager at MD Anderson Cancer Center and Editorial Board Member of Oncology Data Advisor®, stopped by in between presentations to share the most inspiring topics that she enjoyed hearing and is looking forward to sharing with her team.   Oncology Data Advisor: Welcome to Oncology Data Advisor. Today ...
Oncology Data Advisor: Welcome to the Oncology Data Advisor Fellows Forum. Today I have the pleasure of being joined by Dr. Richa Thakur, who is a Palliative Care Physician and a Hematology/Oncology Fellow at Zucker School of Medicine at Hofstra/Northwell Health. Dr. Thakur, thank you so much for coming on today. Richa Thakur, MD: Oh, thank you so much for having me. I'm really excited to be here. Oncology Data Advisor: Would you like you to introduce yourself and share what your work focuses on...
Oncology Data Advisor: Welcome to Oncology Data Advisor. I'm Keira Smith, and today I have the pleasure of being joined by Dr. Christine Ko, who is the host of the See, Hear, Feel podcast. Dr. Ko, thank you so much for coming on the show today. Christine Ko, MD: Thank you, Keira. Thanks for having me. Oncology Data Advisor: Would you like to introduce yourself and what your work and research focus on? Dr. Ko: Sure. I'm a Professor of Dermatology and Pathology at Yale University. Dermatology, for...
Oncology Data Advisor: Welcome to Oncology Data Advisor. I'm Keira Smith. Today I'm joined by Dr. Megan Mullins, who is an Assistant Professor at UT Southwestern Medical Center. Dr. Mullins, thank you so much for coming on today. Would you like to introduce yourself and share what your work focuses on? Megan Mullins, PhD, MPH: Sure. I'm Megan Mullins. I'm an Assistant Professor at UT Southwestern Medical Center's O'Donnell School of Public Health and also the Simmons Comprehensive Cancer Center....
Oncology Data Advisor: In this month of May dedicated to nurses, we have a very inspiring nurse practitioner with us today at Oncology Data Advisor: Dr. Lauren Ghazal, a Family Nurse Practitioner and a Post-Doctoral Research Fellow at the University of Michigan. Her research on work-related challenges and financial toxicity in adolescent and young adult cancer survivors is funded by the National Cancer Institute. Lauren is a cancer survivor, and she is the author of editorial articles featured o...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're here at ONS Congress, and I'm joined by Abbey Kaler. Thanks so much for joining. Abbey Kaler, MS, APRN, FNP-C: Hi, good morning. Thanks for having me. Oncology Data Advisor: Congratulations again on winning the CURE Extraordinary Healer® Award. How does it feel to have won it? Ms. Kaler: Oh my goodness, thank you so much. It's very overwhelming, and I'm really at a loss for words, but I am so very honored and really feel so ap...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, I'm joined by Tony Ellis, who is the Executive Director of the Oncology Nursing Certification Corporation. Thanks so much for coming on today, Tony. Tony Ellis, MSEd, CAE, ICE-CCP: Thanks for having me. Oncology Data Advisor: So, to start off, what is the mission of ONCC? Mr. Ellis: The primary purpose of ONCC is to promote health and safety by validating competence, knowledge, and experience, and by ensuring lifelong learning in on...
Oncology Data Advisor® is excited to announce the launch of the Fellows Forum, a new resource featuring expert perspectives geared toward Hematology/Oncology Fellows. In this interview, Dr. Sunil Iyer, Chief Hematology/Oncology Fellow at the University of Miami, Florida, discusses his leukemia research, exciting new treatment directions, and what to look forward to in the next several years regarding leukemia research.  Oncology Data Advisor: Welcome to the Oncology Data Advisor Fellows For...
Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. We are very excited to announce the launch of our new Fellows Forum, a comprehensive resource for Hematology/Oncology Fellows. Joining me today to announce the launch is Dr. Samuel Kareff, Chief Hematology/Oncology Fellow at the University of Miami, Sylvester Cancer Center. Dr. Kareff, thanks so much for coming on today. To start off, would you like to introduce yourself and share a little bit about your work and your rese...
Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today, for this interview in honor of National Minority Health Month, I'm joined by Dr. Ian Bouligny, who is a Hematology/Oncology Fellow at VCU Massey Cancer Center. Dr. Bouligny, thank you so much for joining me today. To start off, would you like to introduce yourself and say a little bit about what you do? Ian Bouligny, MD: Absolutely, no problem at all. My name is Dr. Ian Bouligny, and I am one of the third-year Hemat...
I think it's those two things—the incredible need for better cancer therapies and the increasing science and the ability to potentially create those therapies—that really led me to this field. by Author Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. In this interview, we're kicking off a new series spotlighting the Oncology Data Advisor Editorial Board. Today I'm joined by board member Dr. Richard Carvajal, who is the Director of Medical Oncology at Northwell Health Ca...
Oncology Data Advisor: Welcome to Oncology Data Advisor. I'm Keira Smith. This April, we're excited to be celebrating National Minority Health Month. Today, I'm joined by Dr. Shakira Grant, who will be sharing her research in the field of health care disparities. Dr. Grant, thank you so much for coming on today. Shakira Grant, MBBS: Hi, I'm Dr. Shakira Grant. I'm an Assistant Professor at the University of North Carolina at Chapel Hill. I spend my time primarily engaged in patient-centered resea...
Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today I'm joined by Dr. Lisa Gudenkauf, who is an Applied Research Scientist in Health Outcomes and Behavior at Moffitt Cancer Center. She's here today to discuss her research regarding patient-reported outcomes for prostate cancer, which was recently presented at the ASCO Genitourinary Cancers Symposium. Dr. Gudenkauf, thank you so much for coming on today. Lisa Gudenkauf, PhD: Hi, my name is Lisa Gudenkauf. I'm an Applie...
Recently, Ravi Parikh, MD, MPP, an Assistant Professor of Medical Ethics and Health Policy and Medicine at the University of Pennsylvania, Perelman School of Medicine, released a research letter titled, "Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval." In this interview with OncData, he further discusses his research and gives a thought-provoking analysis of what these findings could mean for the future of the accelerated app...
Last year, Dr. Ticiana Leal, Director of the Thoracic Medical Oncology Program at Winship Cancer Institute of Emory University, recorded a continuing medical education (CME)/nursing continuing professional development (NCPD)–accredited activity titled Harnessing Immunotherapy-Based Strategies for Advanced Non–Small Cell Lung Cancer (NSCLC). With numerous developments in the field occurring since recording the activity, including new FDA approvals and clinical trial results, Dr. Leal sat down wit...
Oncology Data Advisor: Hi everybody. Welcome to Oncology Data Advisor. Today, we're holding a panel discussion with our Editorial Board in honor of Rare Disease Day. I'm joined by our Editor-in-Chief, Dr. Thomas Abrams, who is an Assistant Professor of Medicine at Harvard Medical School and Institute Physician at Dana-Farber Cancer Institute, and he'll be discussing rare gastrointestinal cancers. Dr. Abrams, thanks for joining today. Thomas Abrams, MD: Oh, it's my pleasure. This is really exciti...
Just under a year ago, Beth Sandy, a Thoracic Oncology Nurse Practitioner, co-led a continuing medical education (CME)/nursing continuing professional development (NCPD)–approved activity, Harnessing Immunotherapy-Based Strategies For Advanced Non–Small Cell Lung Cancer (NSCLC). In this interview, she provides an update on advancements made in treatment and supportive care strategies since recording. Oncology Data Advisor: Welcome to Oncology Data Advisor, a digital resource for the multidiscipl...
In 2022, Allison Imahiyerobo, an Advanced Practice Nurse at the Englewood Health Physician Network in New Jersey, led a continuing medical education (CME)/nursing continuing professional development (NCPD)–approved activity with i3 Health, New Insights and Avenues for Improved Patient Outcomes in Immune Thrombocytopenia. A year later, Ms. Imahiyerobo sat down with Oncology Data Advisor to discuss additional advancements and updates in ITP management and patient care since recording. Oncology Dat...
Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today I'm joined by Dr. Tabernero, who is here to talk about the results of the phase 3 SUNLIGHT trial being presented at the ASCO Gastrointestinal (GI) Cancers Symposium. Dr. Tabernero, thanks so much for joining me today. Josep Tabernero, MD, PhD: Absolutely. My name is Josep Tabernero. I'm a Medical Oncologist based in Barcelona at the Vall d'Hebron Institute of Oncology. My special focus has been always the treatment o...
Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today I'm joined by Dr. Shaji Kumar, Professor of Hematological Malignancies at the Mayo Clinic Cancer Center. Dr. Kumar, thank you so much for joining me today. Since the ASH Annual Meeting just happened recently, would you like to tell us about the abstracts that you presented there? Shaji Kumar, MD: One of the abstracts that we have presented was on the long-term follow-up of the MAIA study. That is a phase 3 trial look...
At the recent San Antonio Breast Cancer Symposium (SABCS), researchers from around the world presented breaking developments in the treatment and care of patients with breast cancer. In this interview, Dr. Jason Mouabbi, an Assistant Professor in the Development of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, shares the four abstracts which he believes will have the greatest impact on practice in the year to come. Oncology Data Advisor: Welcome to Oncology D...
Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today I'm here with Dr. Jason Mouabbi, who is an Assistant Professor in the Department of Breast Medical Oncology at the University of Texas, MD Anderson Cancer Center. Dr. Mouabbi is presenting a poster at the 2022 San Antonio Breast Cancer Symposium, and today he's here to tell us a little bit more about it. Dr. Mouabbi, thank you so much for joining me today. Jason Mouabbi, MD: Good afternoon, everyone. Today we're goin...
With the advent of targeted therapies in lung cancer, patients are experiencing improved outcomes through personalized medicine. However, education regarding potential toxicity is crucial. In this interview, Blanca Ledezma, MSN, NP, shares the importance of setting up expectations for the side effects of targeted therapies for lung cancer and emphasizing communication with the health care team throughout the course of treatment.   Oncology Data Advisor: Welcome to Oncology Data Advisor. Tod...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today I'm joined by Dr. Brian Koffman, who is the founder of CLL Society. Dr. Koffman, thank you so much for being here today. Brian Koffman, MD: My great pleasure, thank you. Oncology Data Advisor: To start off, would you like to tell us a little bit about yourself and your background and how you came to establish CLL Society? Dr. Koffman: Absolutely, thanks. I'm Dr. Brian Koffman. I'm a retired family doctor, and I was diagnosed in 2005 ...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, I'm here with Dr. Christopher Iannuzzi, who is the Medical Director of Physician Services and the Chair of Oncology at Hartford HealthCare, St. Vincent's Medical Center. Dr. Iannuzzi is the Principal Investigator of an ongoing clinical trial for advanced prostate cancer at Hartford HealthCare, and today he's going to tell us some more about this trial, as well as some other advice for prostate cancer screening in light of Men's Heal...
Oncology Data Advisor: Welcome to Oncology Data Advisor, a digital resource for the multidisciplinary cancer team. Today I am joined by Dr. John Mascarenhas from the Icahn School of Medicine at Mount Sinai, New York. Recently, he recorded an educational continuing medical education/nursing continuing professional development (CME/NCPD)–approved activity, Managing Symptom Burden and Optimizing Treatment Outcomes in Myelofibrosis. Today he is here to share with us the importance of participating i...
Ms. Shockney: I love doing the "almost newlywed" game. We use the questions from that game that was on in the 70s, with questions you could print off of the Internet. We buy awards from the Dollar Tree. We've got big baskets of things and they get to select them, which is fun. I'll ask them after we're done, "What did you learn from doing the game?" The answer's always the same is, "I don't know very much about my spouse, or my spouse doesn't know very much about me," or something to that effect...
Oncology Data Advisor: Hi, and welcome to Oncology Data Advisor. Today I'm joined by Lillie Shockney, who is a Professor of Surgery at Johns Hopkins University, and Janie Metsker, who is Clinical Coordinator of the Koontz Center for Advanced Breast Cancer at St. Luke's Hospital. Thank you both so much for being here today. Lillie Shockney, RN, BS, MAS, HON-ONN-CG: Good to see you. Janie Metsker, RN, BSN, CN-BN: Yes, I'm excited that we have this opportunity. Oncology Data Advisor: I know you're ...
Recently, Oncology Data Advisor hosted a live faculty panel discussion in advance of ODACon™ 2022 Supportive Care Summit: Managing Toxicities of Novel Breast Cancer Therapies, featuring the conference's four expert nurse speakers: Dr. Constance Visovsky, Abbey Kaler, Julia LaBarbera, and Janie Metsker. In their conversation, they gave a preview of the educational topics they'll be covering at ODACon on November 12, as well as highlighting their individual research interests and their work in the...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today I'm here with Dr. Samuel Kareff, who is a Hematology-Oncology Fellow at the University of Miami's Sylvester Comprehensive Cancer Center. Dr. Kareff, thank you for joining today. Samuel Kareff, MD: Thanks so much for having me, Keira. Oncology Data Advisor: Definitely. Would you like to tell us a little bit about yourself and your research? Dr. Kareff: Sure. I'm a Clinical Fellow here at the University of Miami's Sylvester Comprehensi...
Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today I'm here with Dr. Valerie Brutus, who is a Breast Surgical Oncologist at St. Vincent's Medical Center of Hartford HealthCare in Connecticut. Since October is Breast Cancer Awareness Month, I know that one of the areas that you're passionate about is breast cancer in transgender patients. Would you like to talk to us a little bit about the risk factors and the screening recommendations for this population? Valerie Bru...
Rahul Banerjee, MD, FACP: Hi, everyone. Welcome to Oncology Data Advisor, your resource for the multidisciplinary cancer team. My name is Dr. Rahul Banerjee, and I'm on the Editorial Board for Oncology Data Advisor. Today, it is my pleasure to speak with Dr. Meier and Dr. Rubinstein about clonal hematopoiesis in hematologic malignancies as we speak about Blood Cancer Awareness Month. Dr. Meier is a Fellow in the Division of Hematology and Oncology at UNC Chapel Hill. His research interests are i...
Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today, I'm here with Dr. Valerie Brutus, who is a Breast Surgical Oncologist at St. Vincent's Medical Center of Hartford HealthCare in Connecticut. Since October is Breast Cancer Awareness Month, one of the important topics to highlight is the fact that men can get breast cancer too. Would you like to tell us a little bit about the risk factors for breast cancer in men, as well as any screening recommendations that exist? ...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today I'm speaking with Blanca Ledezma, who is a Nurse Practitioner at the University of California, Los Angeles (UCLA) Santa Monica. Thank you so much for joining us today. Blanca Ledezma, MSN, NP: I'm Blanca Ledezma. I'm a Nurse Practitioner here in Santa Monica at UCLA Outpatient Oncology. I've been a Nurse Practitioner for over 18 years. My focus is thoracic malignancies. I work with both the clinical research and with the standard of ...
Oncology Data Advisor: Hi everybody, welcome to Oncology Data Advisor. I'm Keira Smith, and today we're having a live expert interview panel in honor of Blood Cancer Awareness Month. I'm joined by one of our Editorial Board members, Dr. Rahul Banerjee, who is an Assistant Professor at the University of Washington. He'll be speaking with Dr. Ajay Major, who is an Assistant Professor at the University of Colorado. Today, they'll be discussing patient-reported outcomes in lymphoma and myeloma. With...
Oncology Data Advisor: Welcome to Oncology Data Advisor, a digital resource for the multidisciplinary cancer team. My name is Lyn Brook. Today I am joined by Donna Catamero of Mount Sinai Hospital, to discuss her presentation from the recent International Myeloma Society Annual Meeting. Thank you for joining us today, Ms. Catamero. Would you like to give a brief introduction of yourself and what you like to research? Donna Catamero, NP: Hi, I'm Donna Catamero. I'm a Nurse Practitioner, and I cur...
Oncology Data Advisor: Welcome to Oncology Data Advisor. I'm Keira Smith. Today I'm here with Dr. Joshua Sasine, who is here to share his advice on caring for patients receiving CAR T-cell therapy. Thank you so much for joining us today. Joshua Sasine, MD, PhD: Sure, I'm a Hematologist-Oncologist and I work at Cedars-Sinai Medical Center. I'm interested in cellular therapies. I routinely do bone marrow transplants and treat patients with CAR T cells. I'm also a physician-scientist, and I have a ...
Oncology Data Advisor: Hi, and welcome to Oncology Data Advisor. Today I'm speaking with Beth Faiman about her recent presentation at the International Myeloma Society Annual Meeting. Dr. Faiman, thank you so much for being here with us today. Beth Faiman, PhD, CNP: Hello, my name is Beth Faiman. I am a Nurse Practitioner and a researcher at the Cleveland Clinic in Cleveland, Ohio. I've been at the Cleveland Clinic since 1994, and I've been fortunate to be working with plasma cell and blood diso...
Oncology Data Advisor: Welcome to Oncology Data Advisor. I'm Keira Smith. Today, I'm here with Dr. Kashyap Patel, who is here to discuss his recent presentation at the International Myeloma Society Annual Meeting. Dr. Patel, thanks so much for joining me today. Kashyap Patel, MD: Of course, of course. Oncology Data Advisor: To start off, would you like to tell us a little bit about your work and what you do? Dr. Patel: As my day job, I work at my own practice that I founded about 20 years back j...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today I'm here with Dr. Valerie Brutus, a Breast Surgical Oncologist at St. Vincent's Medical Center of Hartford Healthcare in Connecticut. Thank you for joining me today. Valerie Brutus, MD, FACS: Thank you so much for having me. Oncology Data Advisor: Of course. Tell us about this new technology, Magtrace. What is it, and how does it work? Dr. Brutus: Magtrace is a magnetic dye, and when it's injected into the breast, it mimics what brea...
Rahul Banerjee, MD, FACP: Welcome to Oncology Data Advisor, a digital resource for the multidisciplinary cancer team. My name is Dr. Rahul Banerjee, and I'm one of the Editorial Board members. Today, it's my honor to be joined by Dr. Ben Derman, who is an Assistant Professor of Medicine at the University of Chicago. What we'll be speaking to him about today is MRD, or measurable residual disease, in multiple myeloma. Dr. Derman is an expert on this topic and is the lead author of a recent study ...
Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today, I'm here at the ASCO Annual Meeting in Chicago, speaking with Urvi Shah from Memorial Sloan Kettering Cancer Center (MSKCC). Thank you for joining us. Would you like to tell us a little bit about yourself? Urvi Shah, MD: Sure. I'm a Hematologist and Oncologist on the Myeloma Service at Memorial Sloan Kettering Cancer Center. I'm happy to be here to talk to you all. Oncology Data: I know you moderated the poster disc...
Oncology Data Advisor: Welcome to Oncology Data Advisor. I am here with Dr. Karen Basen-Engquist at the ASCO 2022 Meeting, where she was part of a very interesting session, a practical toolkit to getting your patients moving and why it matters. Dr. Basen-Engquist, what benefits does exercise have for patients with cancer? Karen Basen-Engquist, PhD, MPH: Oh, exercise is tremendously beneficial for patients with cancer. We have randomized trials that have demonstrated that exercise helps remediate...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're here doing a live interview in honor of World Lung Cancer Day. I'm joined by Beth Sandy, who's one of our editorial board members, as well as Dr. Corey Langer. Thank you both for joining us. Would you like to introduce yourselves? Beth Sandy, MSN, CRNP: I'm Beth Sandy. I'm a Nurse Practitioner in the Cancer Center at the University of Pennsylvania in Philadelphia, and my primary practice specialty is lung cancer. With me, I ha...
Oncology Data Advisor: Welcome to Oncology Data Advisor. I am here with Dr. Jeannie Tie from the Peter MacCallum Cancer Centre at the University of Melbourne and Walter and Eliza Hall Institute. She presented the results of the randomized DYNAMIC trial on adjuvant chemotherapy guided by circulating tumor DNA analysis in stage II colon cancer. This work was also just published in the New England Journal of Medicine. Thank you for joining us, Dr. Tie. Jeanne Tie, MD, MBChB, FRACP: You're welcome. ...
Oncology Data Advisor: Welcome to Oncology Data Advisor. I'm here with Dr. Alexander Spira, Director of the Thoracic and Phase I Program for the Virginia Cancer Specialists, the US Oncology Network. He just presented his research as part of the oral abstract session on non–small cell lung cancer at the ASCO 2022 Annual Meeting, and it is also being published in today's New England Journal of Medicine. Dr. Spira, would you like to comment on the significance of these results of adagrasib for KRAS...
Oncology Data Advisor: Welcome to Oncology Data Advisor, I am Lyn Brook. Today I am joined by Cherry Au, Resident Physician at Rush University Medical Center. Recently at ASCO, she presented her abstract about medical student readiness for treating sexual and gender minority patients with confidence and comfortability. Would you like to begin with introducing yourself and telling us a bit about your interests and what you study? Cherry Au, MD: Yeah. My name is Cherry Au. I'm currently a Postgrad...
Oncology Data Advisor: Welcome to Oncology Data Advisor. I am here with Mark T. Fleming, a Medical Oncologist from the Virginia Oncology Associates, the US Oncology Network, who is at the ASCO 2022 Annual Meeting to present his work on the impact of diversity, equity, and inclusion training in an independent community oncology practice. Thank you for joining us, Dr. Fleming. Mark Fleming, MD: Thank you for having me. Oncology Data Advisor: Thanks. What is the importance of including diversity, e...
Oncology Data Advisor: Would you like to introduce and tell us a bit about yourself? Nick Dionne-Odom, PhD, RN: My name is Nick Dionne-Odom. I'm an Assistant Professor in the School of Nursing at the University of Alabama at Birmingham. Oncology Data Advisor: Would you like to give us an overview of the bias experienced by caregivers regarding cancer-related decisions? Dr. Dionne-Odom: Sure. I partnered with a 401(c)3 called Cancer Care, which is based in New York, to conduct a large national su...
Oncology Data Advisor: Would you like to introduce yourself and give us an overview of your presentations this year at ASCO? Debra Patt, MD, PhD, MBA, FASCO: My name is Dr. Debra Patt. I serve as an Executive Vice President of Texas Oncology, part of the US Oncology Network. And I'm excited, at ASCO, to present information on our digital health solutions. One of the first studies that we presented looks at characteristics of utilization among different patient populations with our digital health...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, I am here with Dr. Charles Simone, an internationally recognized expert in thoracic and radiation oncology and Research Professor and Chief Medical Officer of the New York Proton Center and a member of the Department of Radiation Oncology at Memorial Sloan Kettering Cancer Center. Thanks so much for doing this interview, Dr. Simone. Charles Simone, MD, FACRO: My pleasure. Thank you very much for having me. Oncology Data Advisor: Can...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today I'm joined by Dr. Deb Lundquist, Clinical Research Nurse from Massachusetts General Hospital. Recently, she provided a presentation at the 2022 ASCO Annual Meeting titled Patient-Reported Hope, Quality of Life, Symptom Burden, and Coping Mechanisms in Early Phase Clinical Trial Participants. Would you like to introduce yourself, what you do, and some things you are interested in? Debra Lundquist, PhD, RN: Sure. My name is Deb Lundqui...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, I am joined by Reverend Sean Parker Dennison of Rogue Valley Unitarian Universalist Fellowship in Ashland, Oregon. Recently, Reverend Sean spoke at ONS Congress regarding the topic of improving quality of care for the LGBTQIA+ community. Thank you again, Reverend Sean, for meeting with us today. Could you go ahead and introduce yourself and talk a bit about your interests and what you do? Rev. Sean Parker Dennison: Sure. My name is ...
Oncology Data Advisor: What are some of the biggest challenges in cancer care that patients face in Alaska? Joscelyn VanDuren, MSN, FNP-C: Access to actual care. Given that it's such a large state—70% of the entire US land mass, with more coastline than the entire US combined—we have a very diverse population, and trying to get them from point A to point B can be really difficult. Weather permitting, we can get them where they need to be. However, 75% of Alaska is not on a road system, so they m...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, I'm here with Dr. Diane Von Ah to discuss her recent presentation at ONS Congress. To start us off, would you like to give us an overview of symptom science and what its current state of research is? Diane Von Ah, PhD, RN, FAAN: Symptom science is really a broad term. When we look at symptom science as clinicians and as nurses, we trying to identify the symptoms that are important to our cancer patients. We're working towards identi...
At the recent Oncology Nursing Society (ONS) Congress in Anaheim, California, Bina Parekh, PhD, explained the concept of vicarious trauma and empowered nurses with positive personal growth strategies to deal with challenges, fears, and trauma that stem from dealing with patients with cancer. In this interview with Oncology Data Advisor, Dr. Parekh discusses the concept of vicarious trauma and how nurses, programmed to care for others, are often affected. She shares advice for nurses on how to ad...
Recently, the FDA approved the combination of relatlimab plus nivolumab for patients with unresectable or metastatic melanoma. However, many challenges remain in the selection of patients who will benefit from these agents and in determining alternative options for those who are ineligible for the combination. In this interview in honor of Melanoma Awareness Month, Dr. Benjamin Izar discusses the risk-benefit balance of immunotherapy selection and offers advice for clinicians in how to choose th...
For this interview in honor of Testicular Cancer Awareness Month, Dr. Sam Kaffenberger, an Assistant Professor of Urology at the University of Michigan Health System, explains the importance of taking a nuanced approach to the management of individual patients with testicular cancer, with the goal of minimizing toxicity and achieving the best possible outcomes for treatment and surgery. This interview has been conducted in partnership with the American Urological Association, a premier urologic ...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today I'm here with Dr. Thomas Abrams, our Editor in Chief. Dr. Abrams, thank you so much for joining us today. Thomas Abrams, MD: It's my pleasure. Oncology Data Advisor: So can you give us an overview of the COSMIC-021 trial and the results that your team found? Dr. Abrams: Sure. This is a very preliminary trial. It's one cohort of a larger multicancer trial looking at a specific pair of drugs. One drug is called cabozantinib, which is a...